EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class microbiome therapies, today announced that the investigator-initiated Phase 2a MAST trial (Intestinal Microbiota ...

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases.

Cardiff, Wales-based Antiverse's computational platform has been set up to find antibodies against challenging drug targets, ...

In an era of overt sexism in the sciences, she made two major discoveries, including identifying a chemical signal in the ...

VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet ...

Cytotrait, a biotechnology spinout company from The University of Manchester focussed on the development of novel traits for food and agriculture, announces the close of its £3M seed funding round.

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for ...

This afternoon, we released financial results for the quarter and full year ended December 31, 2025, and recent corporate updates. The press release is available on the Investors section of our ...

RIVKIN Aesthetics reports the rise of weight loss drugs like GLP-1 is reshaping aesthetics, with many new patients seeking ...

Group signs MoU with Korean government and Jeonbuk State to invest nearly KRW 9 trillion in Saemangeum area of Gunsan City, ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

Cash Burn -- $50.2 million in 2025, an improvement from $57.8 million in 2024 due to lower headcount and development costs.